Valid pushback on payer pressure - it's relentless even in rare diseases. But the timing assumptions deserve scrutiny. Isubstrate.com analysis shows why the 18-24 month pre-cliff volatility window might be compressed for ultra-rare indications, plus three indicators that could signal whether Catalyst breaks the pattern: https://vianews.market/corporate-earnings-risk/firdapse-patent-expires-february-2035-threatens-70-80-revenue-decline-for